Comparing the current results to its competitors, Relmada Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 6.71 %, recorded in the same quarter.
Relmada Therapeutics Inc, slower than the average decrease reported by the company's competitors of -4.41 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -4.41 %
Relmada Therapeutics Inc's Comment on Competition and Industry Peers
The pharmaceutical and biotechnology industry is characterized by intense competition and rapid technological advancement. Competitors primarily include large, established pharmaceutical and healthcare companies with substantial financial, marketing, sales, and technical resources. Many of these competitors possess research and development capabilities that may allow them to create new or improved products potentially competing with or rendering the company's products obsolete or uneconomical. The company currently has no products approved for sale.
April 28, 2025
Relmada Therapeutics Unveils Promising Initial Phase 2 NDV-01 Data at AUA2025: A Glimpse into New Frontiers Against Bladder Cancer In a significant development in the fight against high-grade non-muscle invasive bladder cancer (HG-NMIBC), Relmada Therapeutics, Inc. a clinical-stage biotechnology firm, presented promising initial data from its Phase 2 NDV-01 trial at the American Urological Association (AUA) 2025 Annual Meeting. The data, which was shared during the Clinical Trials in Progress session on April 28, 2025, has drawn attention due to its potential implications for patients suffering from this challenging form of cancer. Highlights of the NDV-01 Data Presentation Relmada Therapeutics has been at ...
November 14, 2024
Relmada Therapeutics Inc. a biopharmaceutical company focused on developing innovative therapies for various diseases, recently announced the initiation of Phase 1 dosing of its proprietary psilocybin formulation, REL-P11, aimed at treating metabolic diseases. This move comes at a time when the company faces significant financial pressures, highlighted by a year-on-year revenue decrease of 0% in the second quarter of 2024, contrasting sharply with the 20.46% revenue growth experienced by its competitors in the same time frame. Innovative Approach to Treatment REL-P11 is described as a low-dose, modified-release formulation of psilocybin, a psychoactive compound traditionally associated with psychedelic the...
Diamedica Therapeutics Inc's business model focuses on developing and commercializing innovative therapies to improve patient outcomes in areas of unmet medical needs.
Galmed Pharmaceuticals Ltd's business model focuses on the development and commercialization of innovative therapeutic solutions, particularly in the field of liver and metabolic diseases.
Ironwood Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of medicines for gastrointestinal disorders. Their business model involves discovering, developing, and marketing innovative treatments for conditions like irritable bowel syndrome and chronic constipation. They aim to achieve growth and profitability by leveraging their research capabilities and collaborating with strategic partners in the healthcare industry.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Sources:
Relmada Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Relmada Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
